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Ever since protoporphyrin IX (PpIX) was discovered to accumulate preferentially in cancer cells after 
5-aminolevulinic acid (ALA) treatment,  photodynamic treatment or therapy (PDT) has been developed 
as an exciting new treatment option for cancer patients.  However,  the level of PpIX accumulation in 
oral cancer is fairly low and insuﬃcient for PDT.  Ferrochelatase (FECH) and ATP-binding cassette 
transporter G2 (ABCG2) are known to regulate PpIX accumulation.  In addition,  serum enhances PpIX 
export by ABCG2.  We investigated here whether and how inhibitors of FECH and ABCG2 and their 
combination could improve PpIX accumulation and PDT eﬃcacy in an oral cancer cell line in serum-
containing medium.  ABCG2 inhibitor and the combination of ABCG2 and FECH inhibitors increased 
PpIX in the presence of fetal bovine serum (FBS) in an oral cancer cell line.  Analysis of ABCG2 gene 
silencing also revealed the involvement of ABCG2 in the regulation of PpIX accumulation.  Inhibitors 
of FECH and ABCG2,  and their combination increased the eﬃciency of ALA-PDT even in the pres-
ence of FBS.  ALA-PDT-induced cell death was accompanied by apoptotic events and lipid peroxida-
tion.  These results suggest that accumulation of PpIX is determined by the activities of ABCG2 and 
FECH and that treatment with a combination of their inhibitors improves the eﬃcacy of PDT for oral 
cancer,  especially in the presence of serum.
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-aminolevulinic acid (ALA)-derived protopor-
phyrin IX (PpIX) has been shown to accumulate 
preferentially in cancer cells and proliferating normal 
cells by a regulatory mechanism speciﬁc to these cells 
[1].  When the accumulated PpIX,  which is a ﬂuores-
cent photosensitizer,  is activated by visible light,  
cytotoxic reactive oxygen species (ROS) are generated 
and induce cell death in cancer cells.  Thus,  its appli-
cation for photodynamic diagnosis (PDD) and treat-
ment or therapy (PDT) for cancer patients has been 
developed in various ﬁelds [2-4].  However,  the 
amount of ALA-induced PpIX accumulation in oral 
squamous cell carcinoma (OSCC) cells was found to be 
low,  and PDT has been shown to be less than satis-
factory in vivo [5,  6].  PpIX accumulation in ALA-
treated cells is regulated by various factors such as 
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1) uptake of added ALA [7],  2) metabolism of heme 
synthesis,  such as 5-ALA-hydratase [8],  porpho-
bilinogen deaminase (PBGD) [8,  9],  ferrochelatase 
(FECH) [7,  10],  and heme oxygenase (HO) [11,  
12],  and 3) transport of heme intermediates,  such as 
ABCB6 and ATP-binding cassette transporter G2 
(ABCG2) [13-15].  It has been reported that ABC 
transporters eﬄux photosensitizers,  and that ABCG2 
inhibitors,  such as fumitremorgin C (FTC),  increase 
the intracellular PpIX [16].
　 As pre-malignant and malignant lesions of the oral 
cavity also preferentially accumulate ALA-induced 
PpIX and are accessible by laser light,  they are suit-
able sites for PDD and PDT [5].  It has been noted 
that many of the in vitro PDT investigations have been 
carried out in serum-free culture medium,  even though 
the microcirculation around tumor cells in vivo con-
tains plasma that leaks out from blood vessels [17].  
We previously reported that serum suppressed intra-
cellular ALA-induced PpIX accumulation in human 
urothelial carcinoma cell line T24 due to the action of 
ABCG2,  which exports the PpIX into extracellular 
space [18].  These ﬁndings suggest that the low level 
of PpIX accumulation in OSCC may be due to the 
suppression of PpIX accumulation by plasma.  However,  
the eﬀect of serum on the PpIX accumulation in OSCC 
cells has not been fully investigated.  Thus,  it is 
desirable to carry out experiments in serum-containing 
medium to analyze the mechanism of PDT.
　 As for the cell-death mechanism of ALA-PDT,  2 
pathways have been proposed.  One is the mitochon-
drial pathway and the other is an endoplasmic reticu-
lum stress-induced pathway [19].  It was observed 
that ALA-PDT-treated K562 cells exhibited early 
apoptotic events,  such as dissipation of mitochondrial 
membrane potential and mitochondrial cytochrome c 
release,  but not late apoptotic events,  such as cas-
pase-3 activation or DNA fragmentation [20].  The 
cells eventually died by necrosis through plasma mem-
brane damage.  Moreover,  PpIX was found to sensi-
tize the cells to apoptosis when it existed mainly in the 
mitochondria and to necrosis when it diﬀused into 
other cellular sites,  including the plasma membrane 
[21].  These ﬁndings point to the complexity of ALA-
PDT in cancer cells.
　 In the present work,  we describe the improvement 
of ALA-induced PpIX accumulation in HSC-4,  an 
OSCC cell line,  using various inhibitors of FECH and 
ABCG2,  and improved the eﬃcacy of ALA-enhanced 
PDT in the presence of serum in OSCC.
Materials and Methods
　 Chemicals. ALA and FTC were purchased 
from COSMO OIL (Tokyo,  Japan).  Deferoxamine 
(DFX),  Annexin V-FITC,  FBS,  and propidium 
iodide (PI) were obtained from Sigma (St. Louis,  MO,  
USA).  FTC,  (Z)-1-[N-(2-Aminoethyl)-N-(2-ammonioethyl)-
mino]diazen-1-ium-1, 2-diolate (NOC18),  and swallow- 
tailed perylene derivative of lipid hydroperoxide 
(Spy-LHP) were obtained from Alexis Biochem and 
Dojindo (Kumamoto,  Japan).  10-Nonyl acridine orange 
(NAO) and tetramethylrhodamine-ethyl-ester (TMRE) 
were obtained from Molecular Probes (Eugene,  OR,  
USA).  The monoclonal antibody to ABCG2 was 
obtained from Cell Signaling Technology (Danver,  
MA,  USA).  The FECH antibody was donated by Dr. 
Taketani (Kyoto Institute of Technology,  Japan).  All 
other chemicals were of analytical grade and obtained 
from Nacalai Tesque (Tokyo,  Japan).  NAO and TMRE 
were dissolved in DMSO and stored in aliquots at 4℃ 
until use.
　 Cell culture and ALA treatment. HSC-2 and 
HSC-4 were provided by RIKEN Bio Resource 
Center.  They were maintained in DMEM (Wako,  
Osaka,  Japan) supplemented with 10ｵ FBS,  100U/
ml penicillin,  and 100µg/ml streptomycin.  Cells were 
cultured in a humidiﬁed atmosphere with 5ｵ CO2 at 
37℃ as described previously [22].  The HSC-4 cells 
(1.5×105 cells) were cultured in media containing 
various concentrations of ALA in the presence or 
absence of 10ｵ FBS.
　 Fluorescence microscopy. HSC-4 cells were 
seeded in 3.5-cm dishes and cultured in media contain-
ing various concentrations of ALA (0-2mM) with or 
without 300µM DFX,  300µM Noc-18,  and 10µM 
FTC in the presence or absence of 10ｵ FBS for 3h.  
After treatment with the indicated concentration of 
ALA for 3h,  HSC-4 cells were stained with 10nM 
NAO for 10min at 37℃ and then observed by ﬂuores-
cence microscopy (Zeiss,  Axiovert 200) with a 100-W 
halogen lamp.  Fluorescence images were taken using 
a highly light-sensitive thermo-electrically cooled 
charge-coupled device camera (ORCAII-ER,  
Hamamatsu,  Japan).  NAO for detection of mitochon-
dria,  a G365-nm excitation ﬁlter,  a FT580-nm beam 
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splitter,  and an up-to-LP590-nm emission ﬁlter for 
PpIX were also used [22,  23].
　 Exposing light and PDT analysis. In the 
presence of FBS,  HSC-4 cells were incubated with 
1.0mM ALA at 37℃ for 3h in the presence or 
absence of 10µM FTC and 300µM Noc18,  then 
exposed to light for 20min.  Then,  we changed the 
medium and cultured at 37℃ for 6h in the presence 
of FBS.  Next,  the cells were stained with Annexin 
V/PI or TMRE and analyzed using a ﬂow cytometer.  
As a light source,  an Na-Li lamp (TheraBeam VR630,  
USHIO,  Tokyo,  Japan) was used.  The wavelength of 
light was 600-700nm.  The light intensity was 9.6 
J/cm2 [22-24].  ALA-PDT-treated cells were stained 
using a TACSTM Annexin V/PI Apoptosis Detection 
kit (Trevigen) and 100µM TMRE,  according to the 
manufacturerʼs instructions.  Then,  the cells were 
analyzed by ﬂow cytometry.
　 The 100µM z-VAD-fmk was applied at the same 
time as ALA application and FBS(＋) medium change,  
then reapplied with FBS(＋) medium.  After 6h,  the 
proportion of cell death,  apoptotic and necrotic cells 
was measured by ﬂow cytometry.
　 Lipid peroxidation by ALA-PDT of cells was 
analyzed as previously described using a new ﬂuores-
cent probe,  Spy-LHP [23,  25,  26],  which reacted 
rapidly and quantitatively with lipid hydroperoxides to 
form the corresponding oxide,  Spy-LHPOx,  which 
emits extremely strong ﬂuorescence in the visible 
range (em＝535-574nm).  In the presence of FBS,  
HSC-4 cells were incubated with 1.0mM ALA at 
37℃ for 3h in the presence or absence of 10µM 
FTC and 300µM Noc18,  exposed for 20min to light,  
and cultured at 37℃ for 10min in the presence of 
FBS medium.  Cells were incubated with 1µM Spy-
LHP for 10min before ALA-PDT.  Then,  the cells 
were analyzed using a ﬂow cytometer (FL1).
　 Flow cytometric analysis. Upon incubation 
with ALA,  the cells grown on dishes were removed by 
treatment with trypsin.  ALA-treated cells were ﬁl-
tered through a 50-µm nylon mesh (SEFER,  Heiden,  
Switzerland).  Then,  the ﬂuorescence intensity of the 
cells was measured using a Fluorescence-Activated 
Cell Sorter (BD,  CA,  USA).  A total of 10,000 cells 
were analyzed for each sample (ex/em＝488/650nm) 
[10,  22,  23].  PpIX was measured by ﬂow cytometry 
using FACScan FL3-H.
　Western blotting analysis. Cell specimens 
were subjected to SDS-polyacrylamide gel electro-
phoresis and proteins in the gel were transferred 
electrophoretically onto an Immobilon membrane 
(Millipore,  Waltham,  MA,  USA).  This membrane 
was probed with primary antibodies (1 : 1,000 mouse 
anti-human actin antibody,  3 : 1,000 rabbit anti-human 
ABCG2 antibody,  1 : 100 rabbit anti-bovine FECH 
antibody) and secondary antibodies using the SNAP 
i.d.  system (Millipore),  according to the manufac-
turerʼs instructions.  Immunoreactive bands were 
visualized using an ECL system (Amersham Biotech,  
Uppsala,  Sweden) [23].
　 RT-PCR analysis. To determine the expres-
sion of ferrochelatase and ABCG2 transcriptions,  
RT-PCR was performed as follows.  Total RNA was 
isolated from cells using TRIzol (Invitrogen) following 
the manufacturerʼs instructions.  Oligo dT-primed 
cDNA was prepared from 1 ug of total RNA using 
Superscript II (Invitrogen).  One-twentieth of each 
obtained cDNA specimen was used for PCR.  Primers 
were designed on the basis of sequences of human 
ferrochelatase [27],  human ABCG2 [28],  and human 
acidic ribosomal phosphoprotein 36B4 [29,  30].  
36B4 is a housekeeping gene that is expressed con-
stantly in tissue.  Ampliﬁcation of ferrochelatase,  
ABCG2,  and the positive control 36B4 was carried 
out using forward primer 5ʼ-CGCAGAAGAGGA 
AGCCGAAAAC-3ʼ and reverse primer 5ʼ-GGTCGC 
CTCTGTTGACCACAGA-3ʼ for ferrochelatase,  
forward primer 5ʼ-GATCTCTCACCCTGG 
GGCTTGTGGA-3ʼ and reverse primer 5ʼ-TGTGCA 
ACAGTGTGATGCAAGGGA-3ʼ for ABCG2,  and 
forward primer 5ʼ-TGCCAGTGTCTGTCTGCAGA 
-3ʼ and reverse primer 5ʼ-ACAAAGGCAGATGGA 
TCAGC-3ʼ for 36B4.  The PCR reaction was carried 
out with an initial period at 95℃ for 4min,  then 35 
cycles at 95℃ for 1min,  60℃ for 1min,  and 72℃ 
for 1min.  The PCR products were separated by 1.2ｵ 
(w/v) agarose gel electrophoresis and detected with 
ethidium bromide under UV light.
　 ABCG2 siRNA transfection. Three diﬀerent 
Stealth ABCG2 siRNA duplexes (Invitrogen) were 
used in combination with transient inhibition of 
ABCG2 gene expression in HSC-4 cells as described 
previously [31].  HSC-4 cells were incubated with 
lipofectamine RNAi MAX transfection reagent 
according to the reverse transfection protocol pro-
vided by the manufacturer.  Stealth ABCG2 siRNA 
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was used as a pool in equal proportions at a ﬁnal 
concentration of 50nM.
　 Statistical analysis. Statistical analysis was 
carried out using Studentʼs t test (SPSS 11.0 for 
Windows).  Results are expressed as means ± SDs,  
and p values ＜0.05 were considered to indicate sig-
niﬁcant diﬀerences.
Results
　 Accumulation of PpIX in ALA-treated OSCC.
To conﬁrm the eﬀect of serum on intracellular PpIX 
accumulation in OSCC cell lines,  cells from HSC-4,  
a human tongue carcinoma cell line,  and HSC-2,  a 
human oral squamous carcinoma cell line,  were 
treated with ALA in the presence and absence of 
FBS (Fig.  1).  As shown in Figs.  1A and B,  the 
accumulation of intracellular PpIX in these cell lines 
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Fig. 1　 ALA-mediated PpIX accumulation in OSCC.  (A,  B) Accumulation of ALA-induced PpIX in HSC-4 and HSC-2 cells after incuba-
tion with the indicated concentrations of ALA in the presence or absence of FBS for 3h.  HSC-4 (A) and HSC-2 (B) cells were exposed to 
0-2.0mM ALA for 3h.  PpIX accumulation was analyzed by ﬂow cytometry.  Filled and open circles show the PpIX values in the presence 
and absence of serum,  respectively.  Values are the means ± SDs derived from three independent experiments.  Asterisks indicate signiﬁ-
cant diﬀerences from the corresponding FBS(－) samples.  (C) Accumulated PpIX was observed by ﬂuorescence microscopy after ALA 
treatment in the absence or presence of FBS.  Merged pictures (mitochondria and PpIX) are shown.
was increased in an ALA dose-dependent manner,  and 
the accumulations in the presence of FBS were sig-
niﬁcantly reduced compared with those in the absence 
of FBS (at 1.0mM,  30ｵ decrease in HSC-4,  50ｵ 
decrease in HSC-2).  The PpIX accumulation in 
HSC-4 was lower than that in HSC-2.  Fig.  1C shows 
the accumulated PpIX in HSC-4 cells,  observed by 
ﬂuorescence microscopy.  Since the aim of this study 
was to improve PDD and PDT in oral cancer cells 
having low capacity for PpIX accumulation in the 
presence of serum,  the subsequent experiments were 
performed with HSC-4.
　 Enhancement of PpIX accumulation by the 
inhibitors FECH and ABCG2 and their combi-
nation. Heme biosynthesis by FECH,  which is a 
NO-sensitive enzyme,  requires iron and PpIX as 
substrates; then the iron chelator DFX and NO donor 
NOC18 can increase the intracellular ALA-induced 
PpIX accumulation [10,  32].  In addition,  since ABCG2 
exports PpIX,  its speciﬁc inhibitor FTC eﬀectively 
increases the intracellular PpIX [14].  Thus,  we 
investigated whether FECH and ABCG2 inhibitors 
and their combination could improve the ALA-induced 
PpIX accumulation in HSC-4.  First,  we conﬁrmed 
the gene and protein expression of FECH and ABCG2 
in HSC-4 (Fig.  2A and B).  Both mRNA and protein 
expressions of FECH and ABCG2 were detected in 
HSC-4 cells.
　 In the absence of serum,  both DFX and Noc18,  but 
not FTC,  signiﬁcantly increased the PpIX accumula-
tion,  by 5.0- and 5.2-fold,  respectively (Fig.  2C).  In 
contrast,  in the presence of serum,  FTC but neither 
DFX nor Noc18,  signiﬁcantly increased the PpIX 
accumulation,  by 2.9-fold (Fig.  2D).  The combination 
of FTC and Noc18 strongly enhanced PpIX accumula-
tion in HSC-4 in both the presence (4.4-fold) and 
absence (11.2-fold) of serum.
　 To conﬁrm visually the increase of intracellular 
PpIX by FECH and ABCG2 inhibitors in HSC-4 
cells,  intracellular PpIX was assessed by ﬂuores-
cence microscopy (Fig.  2E).  We used NAO to detect 
the mitochondria.  In the absence of FBS,  Noc18 
increased the accumulation of PpIX.  DFX also 
induced a similar increase (data not shown).  In con-
trast,  in the presence of FBS,  FTC increased the 
accumulation of PpIX,  and related intracellular dis-
tributions were observed in the mitochondria and 
cytosol.  Thus,  it seems that PpIX export by ABCG2 
in the presence of serum is a major determinant of 
PpIX accumulation in HSC-4.
　 Eﬀect of ABCG2 gene silencing on intracel-
lular PpIX accumulation in HSC-4. To deter-
mine whether ABCG2 plays a critical role in the eﬄux 
of PpIX in HSC-4 cells,  we developed a washing 
method for the release of accumulated PpIX from cells 
after incubation with ALA (Fig.  3).  Fig.  3A shows 
the experimental procedure.  First,  we used ABCG2 
siRNA transfection.  We observed the largest silenc-
ing eﬀect on ABCG2 mRNA expression by the trans-
fection of 50nM siRNA (Fig.  3B).  Protein levels of 
ABCG2 were also downregulated by RNAi (Fig.  3C).  
Then,  we used this siRNA concentration for a wash-
ing method.
　 Fig.  3D shows the eﬀect of FTC,  Noc18,  and 
both on the amount of accumulated PpIX after washing 
cells with FBS-containing ALA-free medium.  The 
accumulated PpIX decreased after washing the cells.  
The level of accumulated PpIX was increased by FTC 
and FTC＋Noc18 in the presence of FBS.  After the 
RNAi treatment,  1) the accumulated PpIX in ALA-
treated cells did not decrease after washing the cells.  
Moreover,  2) treatment with Noc18 substantially 
increased the cellular level of PpIX (Fig.  3E).  In 
contrast,  3) the eﬀects of FTC and FTC＋Noc18 on 
the PpIX level were about the same as those in Fig.  
3D.  These results indicated that ABCG2-mediated 
PpIX eﬄux might be an important pathway for the 
regulation of the PpIX level in FBS-containing 
medium in HSC-4 cells.
　 Enhancement of the eﬃcacy of PDT by the 
combination of ABCG2 and FECH inhibitors.
We next developed an experimental procedure to 
conﬁrm the ALA-PDT eﬀect in HSC-4 cells treated 
with ABCG2 and FECH inhibitors in the presence of 
FBS (Fig.  4A).  ALA-PDT-induced cell death with 
various inhibitors was analyzed by a forward-scatter/
side-scatter (FSC/SSC) scattergram using ﬂow 
cytometry.  We counted fewer FSC events,  which 
reﬂect cell membrane fragmentation,  cell shrinkage,  
and the formation of apoptotic bodies (Fig.  4B).  Cell 
death was induced signiﬁcantly by ALA-PDT with 
FTC,  and the highest level of cell death was observed 
in ALA-PDT with FTC＋Noc18 or FTC＋DFX.  
Phosphatidylserine (PS) externalization,  a feature of 
early apoptotic cell death,  and disruption of cell 
membrane integrity,  a feature of necrotic or late 
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apoptotic cell death,  were analyzed by Annexin-V/PI 
staining and ﬂow cytometry.  As shown in Fig.  4C and 
D,  early apoptotic cell death by ALA-PDT was sig-
niﬁcantly promoted by FTC or DFX,  and disruption 
of cell membrane integrity by ALA-PDT was also 
promoted by FTC.  Furthermore,  late apoptotic or 
necrotic cell death was strongly promoted by the 
combination of FECH and ABCG2 inhibitors in paral-
lel with a decrease of FTC,  as shown in Fig.  4B.  In 
addition,  we analyzed the changes in mitochondrial 
membrane potential in cells using TMRE staining,  and 
observed depolarization of the membrane potential,  
which occurred in parallel with cell death (Fig.  4E).  
Figs.  4B-E show that ALA-PDT-induced cell death 
involves apoptosis.
　 Eﬀect of z-VAD-fmk on ALA-PDT by the 
inhibitors ABCG2 and FECH and their combi-
nation. Next,  we veriﬁed the potential of ALA-
158 Acta Med.  Okayama　Vol.  67,  No.  3Yamamoto et al.
500
HSC-4MW
36B4 FECH ABCG2
100
200
300
(bp)
A
B
FECH
Actin
ABCG2
C
0
500
1,000
1,500
2,000
2,500
3,000
Cont ALA +FTC +FTC
+Noc
Pp
IX
(%
 o
f c
on
tro
l)
FBS (－)
+DFX+Noc
＊
＊
＊
D
Pp
IX
(%
 o
f c
on
tro
l)
Cont ALA +FTC +FTC
+Noc
+DFX+Noc
FBS (+)
200
400
600
800
1,000
1,200
1,400
0
＊
＊
+Noc 
＋FTCALA
E FBS (＋) 1.0 mM ALA (3 h), ＋/－inhibitor 
+FTC+Noc 
Fig. 2　 Eﬀect of ABCG2 and FECH inhibitors on PpIX accumulation in HSC-4 cells.  (A) mRNA expressions of ABCG2 and FECH in 
HSC-4 were detected by RT-PCR.  (B) Protein expressions of ABCG2 and FECH in HSC-4 were detected by western blotting.  
ABCG2: approx.  72kDa,  FECH: approx.  42kDa,  Actin: approx.  42kDa.  (C,  D) Eﬀect of ABCG2 and FECH inhibitors and their combi-
nation on ALA-mediated PpIX accumulation in HSC-4 cells.  HSC-4 cells were incubated with the indicated concentration of ALA with or 
without 300µM DFX,  300µM Noc-18,  and 10µM FTC for 3h in the absence (C) or presence of FBS (D).  PpIX accumulation was analyzed 
by ﬂow cytometry.  Values are the means ± SDs derived from three independent experiments.  Asterisks indicate signiﬁcant diﬀerences 
from the corresponding ALA samples.  (E) Accumulated PpIX and mitochondria were observed by ﬂuorescence microscopy after ALA and 
inhibitor treatment in the presence of FBS.  Mitochondria were stained with NAO.
159Improvement of Eﬃcacy of ALA-PDTJune 2013
2.2%
Re
la
tiv
e 
AB
C
G
2 
m
RN
A 
le
ve
l( /
36
B4
) (
%
)
5%
Re
la
tiv
e 
AB
C
G
2 
pr
ot
ei
n 
le
ve
l (
/c
on
tro
l) 
(%
)
CB
100
MW
200
300
(bp)
Control
+ ABCG2
siRNA
36B4 ABCG2 36B4 ABCG2
A
ED
Time (h)
Pp
IX
(%
 o
f c
on
tro
l)
Time (h)
Pp
IX
(%
 o
f c
on
tro
l)
ABCG2 siRNA
0
200
400
600
800
1,000
1,200
1,400
0 1.5 3 4.5
After washFBS(-)
+ALA FBS(+) -ALA
Control
0
200
400
600
800
1,000
1,200
1,400
0 1.5 3 4.5
Wash
After washFBS(-)
+ALA FBS(+) -ALA
None
FTC+Noc
FTC
Noc
ABCG2 siRNA
50 nM
0
20
40
60
80
100
120
24.4%
100%
3 nM0 nM
FACScan analysis
1.5  h
2.0 mM ALA Wash and change medium (FBS (+))
+/- inhibitors
3h FACScan
analysis
FBS (-) FBS (+)Transfection 4 days
Control
Actin
ABCG2
+ ABCG2
siRNA
0
20
40
60
80
100
120
Control
100%
+ ABCG2
siRNA
Fig. 3　 Silencing of ABCG2 expression in HSC-4 cells and its eﬀect on the sensitivity to FTC and/or Noc-18 in ALA-mediated PpIX 
accumulation.  (A) Experimental schedule of ABCG2 gene silencing and ALA-mediated PpIX accumulation.  (B) Expression of ABCG2 
mRNA was detected by RT-PCR after 4 days of transfection with gene-speciﬁc siRNA.  (C) Protein expressions of ABCG2 and FECH were 
detected by western blotting after 4 days of transfection.  (D,  E) HSC-4 cells were incubated with 2.0mM ALA for 1.5h in FBS-free culture 
medium,  and the cells were washed with FBS-containing incubation medium in the presence or absence of 10µM FTC or 300µM Noc-18.  
The content of PpIX in the cells was measured using a ﬂow cytometer.  Cellular PpIX accumulation without (D) or with (E) siRNA transfec-
tion.  Values are the means ± SD derived from 3 independent experiments.
160 Acta Med.  Okayama　Vol.  67,  No.  3Yamamoto et al.
A
G
CB
D E
F
C
ou
nt
s
Spy-LHP (FL1-H)
10 410 210 0 10 310 1
0
40
80
12
0
16
0
20
0
ALA +FTC +Noc
Control
La
te
 a
po
pt
ot
ic
 o
r n
ec
ro
tic
 c
el
ls
(%
)
M
em
br
an
e 
de
po
la
riz
at
io
n
(%
)
3h 6h FACScan
analysis
Light 1.0mM ALA+/- inhibitors
FBS(+) FBS(+)
FBS (+) medium change
PDT 9.6J/cm2
0
20
40
60
80
100
Cont ALA +FTC +Noc +FTC
+Noc
*
*
*
C
el
l d
ea
th
 (%
)
0
10
20
30
40
50
*
*
*
Cont ALA +FTC +Noc +DFX +FTC +FTC
+Noc +DFX
0
Control DMSO ALA +FTC
+Noc
+FTC
+Noc
+z-VAD
10
20
30
40
*
Control ALA +FTC +Noc +DFX +FTC +FTC
+Noc +DFX
0
10
20
30
40
50
60
* *
*
Ea
rly
 a
po
pt
ot
ic
 c
el
ls
(%
)
Control ALA +FTC +Noc +DFX +FTC +FTC
+Noc +DFX
0
10
20
30
40
50
60
*
*
*
*
*
C
el
l d
ea
th
(%
)
Fig. 4　 Enhancement of ALA-PDT-induced cell death by ABCG2 and FECH inhibitors in combination in HSC-4.  (A) Experimental 
schedule of PDT with the combination of ABCG2 and FECH inhibitors.  (B) Presence of cell death in FSC/SSC plot after PDT.  The FSC-
decreased cells were deﬁned as dead cells.  Asterisks indicate signiﬁcant diﬀerences from the corresponding ALA samples.  (C,  D) Cells 
were stained with Annexin V/PI after PDT and analyzed by ﬂow cytometry.  PS-externalized and PI-stained cells: late apoptotic or necrotic 
cells (C).  Phosphatidylserine (PS)-externalized cells: early apoptotic cells (D).  Values are the means ± SDs derived from 3 independent 
experiments.  Asterisks indicate signiﬁcant diﬀerences from the corresponding ALA samples.  (E) Mitochondrial membrane potential was 
detected by TMRE staining after the ALA-PDT,  and analyzed by ﬂow cytometry (FL-2).  Values are the means ± SDs derived from 3 
independent experiments.  Asterisks indicate signiﬁcant diﬀerences from the corresponding ALA samples.  (F) Eﬀect of pan-caspase inhibi-
tor z-VAD-fmk on the ALA-PDT-induced cell death.  Experimental schedule is the same as in (B).  The proportion of cell death was mea-
sured by ﬂow cytometry.  Values are the means ± SDs derived from 3 independent experiments.  Asterisks indicate signiﬁcant diﬀerences 
from the corresponding＋FTC＋Noc-18 samples.  (G) Lipid peroxidation.  The cells were subsequently analyzed using a ﬂow cytometer.
PDT-induced cell death to involve the apoptotic 
pathways.  To investigate whether caspases play a role 
in the cell death that follows ALA-induced PDT,  the 
eﬀect of PDT on cell death was evaluated in the 
absence and presence of the pan-caspase inhibitor 
z-VAD-fmk (Fig.  4F).  The proportion of cell death 
was signiﬁcantly decreased in the presence of z-VAD-
fmk (20ｵ decrease),  suggesting the involvement of a 
caspase-dependent apoptotic pathway in this cell death 
mechanism.
　 Induction of lipid peroxidation in ALA-PDT 
by the combination of ABCG2 and FECH 
inhibitors. It was reported that PDT produces a 
singlet oxygen and induces lipid peroxidation in vitro 
and that photodynamic peroxidation of cellular lipids 
is a consequence of PDT associated with cytolethality.  
To examine the eﬀect of PDT on lipid peroxidation,  
we used Spy-LHP.  The ﬂuorescence intensity of Spy-
LHP was increased a short time after PDT,  suggest-
ing the involvement of lipid peroxidation at an early 
stage of this cell death mechanism (Fig.  4G).
Discussion
　 The OSCC cell line HSC-4 showed a low level of 
ALA-induced PpIX accumulation,  and the eﬃcacy of 
ALA-PDT in the cells was insuﬃcient.  The combina-
tion of inhibitors of heme synthesis and ABCG2 
improved the accumulation and eﬃcacy of ALA-PDT 
in HSC-4,  especially by the inhibition of PpIX release 
through ABCG2 in the presence of FBS (Fig.  5).  
Export of PpIX by ABCG2 might be a key factor in 
determining the eﬃcacy of ALA-PDT in an in vivo 
environment of oral cancer.  This is the ﬁrst report on 
the eﬃcacy of ABCG2,  FECH inhibitors,  and their 
combination for ALA-PDT in FBS-containing medium 
in OSCC cell lines.  No report about this treatment 
has been previously published.
　 Previously,  the amount of ALA-induced PpIX in 
OSCC was found to be low,  and PDT in oral cancer 
patients has been unsatisfactory [5,  6].  It has also 
been shown that several factors are involved in the 
regulation of ALA-induced PpIX accumulation and that 
the decrease of intracellular PpIX is regulated by the 
PpIX metabolic pathway and eﬄux pathways [4-10,  
33,  34].  FECH is the terminal enzyme of the heme-
biosynthetic pathway and is thought to be the rate-
limiting step for heme synthesis.  ABCG2 is a trans-
porter in the cell membrane for heme intermediates 
and is thought to regulate the traﬃc of PpIX in the 
presence of serum.  In this study,  ABCG2 and FECH 
inhibitors and their combination improved the ALA-
induced PpIX accumulation in OSCC.  These ﬁndings 
suggested that the combination of ABCG2 and FECH 
inhibitors might improve the eﬃcacy of ALA-PDT in 
oral cancer patients.
　 It has been reported that ABCG2 is localized at the 
plasma membrane and provides a mechanism to remove 
excess porphyries to maintain intracellular porphyry 
homeostasis and that ABCG2 acted to modulate por-
phyry concentrations under normal conditions [17].  
Thus,  ABCG2 can appropriately control the level of 
intracellular PpIX.  The present study is the ﬁrst to 
reveal the involvement of ABCG2 in ALA-mediated 
PpIX accumulation in medium containing FBS using 
knockdown of ABCG2 in HSC-4 (Fig.  3).  These ﬁnd-
ings indicated that the increase of ALA-mediated 
PpIX accumulation in cancer cells by ABCG2 inhibi-
tors is important,  especially for clinical applications.  
In this context,  several ﬁndings have previously been 
made on the eﬀects of serum and ABC transporters on 
PpIX accumulation in ALA-treated cells: 1) Serum 
inhibited the PpIX accumulation in several cells [35-
37]; 2) Serum increased the release of accumulated 
PpIX to extracellular space [38,  39]; 3) Serum 
induced a diﬀerent localization of synthesized PpIX in 
ALA-treated cells [40]; 4) ABCG2-expressing cells 
accumulated a low level of ALA-mediated PpIX [41];  
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Fig. 5　 Schematic representation of the mechanism of ALA-
mediated PpIX accumulation improved by the combination of 
ABCG2 and FECH inhibitors in HSC-4.
5) An ABCG2 inhibitor suppressed the export of 
PpIX from cells to the extracellular space and 
increased the PpIX accumulation [14]; 6) ABCG2 
mediated the transport of photosensitizers [16];  
7) Both PpIX and heme bound to the ECL3 (ABCG2 
large extracellular loop) region in transmembrane 
spans 5 and 6 of ABCG2,  and human serum albumin 
could be one of the possible partners for its removal 
[42]; and 8) PpIX bound to BSA [33].  On the basis 
of these ﬁndings,  it was concluded that ALA-PDT 
was strongly enhanced by the FECH inhibitor in 
combination with that of ABCG2 (Fig.  4).  This could 
be a new method to improve photodynamic therapy for 
OSCC.  Recently,  it was reported that ABCG2 was 
distributed not only in the cell membrane but also in 
the inner membrane of mitochondria [34] and that the 
ABCG2 protein is sensitive to FTC.  Thus,  further 
study is required to clarify the role of ABCG2 in the 
molecular mechanism of PpIX accumulation in various 
cells including HSC-4 cells.
　 It is preferable to induce the apoptotic rather than 
necrotic cell death of target cancer cells by PDT 
because apoptotic cell death does not aﬀect the adja-
cent normal cells.  Previously,  it was reported that the 
subcellular localization of PpIX might aﬀect the type 
of cell death,  i.e.,  apoptosis or necrosis [23].  Light 
exposure of cells containing PpIX,  which was distrib-
uted in the mitochondria or the cytosol,  induced 
apoptosis and necrosis,  respectively,  in an epithelial 
breast tumor line [21].  It was also reported that 
ALA-PDT induced apoptotic cell death in human oral 
cancer Ca9-22 cells [43].  In this experiment,  the 
distributions of accumulated PpIX by treatment with 
ABCG2 inhibitor and a combination of ABCG2 and 
FECH inhibitors were observed in the cytosol and 
mitochondria of HSC-4 (Fig.  2),  and both apoptosis 
and necrosis could be induced after ALA-PDT with 
the combination of these inhibitors (Fig.  4).  In addi-
tion,  a pan-caspase inhibitor suppressed only 20ｵ of 
the cell death.  In this context,  it was reported that 
both caspase-dependent and -independent apoptotic cell 
death was induced by ALA-PDT in human lymphoma 
cells [44].  These ﬁndings suggested that the major 
part of PDT-induced cell death promoted by the com-
bination of ABCG2 and FECH inhibitors was caspase-
independent apoptotic cell death and/or necrotic cell 
death.  Necrotic cell death could lead to inﬂammation 
in the surrounding tissue.  Thus,  improvement of the 
rate of necrotic cell death among the total cell death 
is our next subject for study.
　 Apoptosis also occurred at least partly in HSC-4 
cells after ALA-PDT,  and the apoptotic process may 
be induced by the loss of mitochondrial function.  In 
this context,  there was evidence of mitochondrial 
swelling accompanied by loss of mitochondrial mem-
brane integrity and autophagic vacuolization of the 
cytoplasm [45].  Reactive oxygen species scavengers 
delay the progression of mitochondrial depolarization 
and apoptotic cell death [46].  In this study,  we 
observed membrane potential depolarization and 
increased lipid peroxidation after ALA-PDT with the 
combination of ABCG2 and FECH inhibitors.  However,  
a preliminary experiment showed no autophagic 
change.  In addition,  ALA-PDT-induced apoptosis 
with the combination of ABCG2 and FECH inhibitors 
was suppressed by the pan-caspase inhibitor zVAD-
FMK.  These ﬁndings showed that cell death induced 
by ALA-PDT with the combination of ABCG2 and 
FECH inhibitors in HSC-4 was accompanied by mito-
chondrial depolarization and lipid peroxidation,  which 
is a zVAD-FMK-inhibitable mechanism.  Taking these 
ﬁndings together,  we propose the following causal 
sequence of apoptosis induced by ALA-PDT with the 
combination of inhibitors in HSC-4: i) intracellular 
generation of ROS such as singlet oxygen by ALA-
PDT is the initial event; ii) lipid peroxidation by the 
ROS induces mitochondrial membrane disruption 
accompanied by mitochondrial depolarization;  
iii) cytochrome c is probably released from mitochon-
dria,  activating the caspase cascade; and (iv) this 
cascade induces chromatin condensation and PS exter-
nalization.  On the other hand,  singlet oxygen and lipid 
peroxide induction by ALA-PDT might also induce the 
disruption of the plasma membrane,  which in turn 
induces necrotic cell death.
　 A group of heme proteins,  the cyclooxygenases 
(COXs),  are key enzymes required for the conversion 
of arachidonic acid to prostaglandins.  In addition,  
Karthein et al.  reported the involvement of ferryl-
PpIX in the catalytic mechanism of COX [47].  It was 
reported that COX-2 mRNA was detectable in the 
HSC2,  but not in HSC-4 [48].  In this context,  our 
results showed that the PpIX accumulation in HSC-2 
was higher than in HSC-4.  These ﬁndings suggest that 
the expression level of a heme protein,  such as COX-
2,  is involved in the level of intracellular PpIX accu-
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mulation.
　 The investigations reported in this paper have 
revealed a novel method to increase PpIX accumula-
tion and improve the eﬃcacy of ALA-PDT in HSC-4.  
These ﬁndings should promote the development of new 
anticancer therapeutic modalities.
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